| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| SELL | SELL | SELL | SELL | SELL |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | 1.25▼ | 1.24▼ | 1.24▼ | 1.28▼ | 1.22▲ |
| MA10 | 1.26▼ | 1.27▼ | 1.27▼ | 1.32▼ | 1.27▼ |
| MA20 | 1.30▼ | 1.32▼ | 1.32▼ | 1.23▲ | 1.13▲ |
| MA50 | 1.29▼ | 1.25▼ | 1.23▲ | 1.26▼ | 1.56▼ |
| MA100 | 1.22▲ | 1.24▼ | 1.25▼ | 1.15▲ | 1.77▼ |
| MA200 | 1.27▼ | 1.21▲ | 1.18▲ | 1.46▼ | 3.05▼ |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | -0.010▼ | -0.016▼ | -0.017▼ | -0.001▼ | 0.047▲ |
| RSI | 40.094▼ | 42.520▼ | 43.932▼ | 48.125▼ | 47.113▼ |
| STOCH | 11.111▼ | 8.333▼ | 8.333▼ | 45.822 | 54.120 |
| WILL %R | -100.000▼ | -100.000▼ | -100.000▼ | -55.245 | -40.921 |
| CCI | -79.576 | -88.536 | -89.668 | -24.522 | 37.396 |
|
Wednesday, April 16, 2025 06:30 AM
Exemption from the $5.1 million repayment obligation strengthens LAVA’s balance sheetUnderscores focus on cost curtailment and strategic option ...
|
|
Wednesday, April 16, 2025 12:30 AM
UTRECHT, The Netherlands and PHILADELPHIA, April 16, 2025 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (NASDAQ: LVTX, “LAVA,” “the Company”), a clinical-stage ...
|
|
Friday, April 04, 2025 05:00 PM
LAVA Therapeutics (NASDAQ:LVTX – Free Report) – Equities research analysts at HC Wainwright issued their Q1 2025 earnings per share estimates for LAVA Therapeutics in a note issued to ...
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 01/05/25 | 1.239 | 1.28 | 1.22 | 1.24 | 9,377 |
| 30/04/25 | 1.26 | 1.26 | 1.20 | 1.25 | 73,103 |
| 29/04/25 | 1.30 | 1.30 | 1.30 | 1.30 | 405 |
| 28/04/25 | 1.33 | 1.33 | 1.28 | 1.28 | 12,187 |
| 25/04/25 | 1.39 | 1.39 | 1.28 | 1.31 | 25,601 |
| 24/04/25 | 1.304 | 1.40 | 1.304 | 1.38 | 10,642 |
| 23/04/25 | 1.41 | 1.4375 | 1.32 | 1.36 | 40,099 |
| 22/04/25 | 1.3902 | 1.41 | 1.38 | 1.38 | 53,343 |
| 21/04/25 | 1.31 | 1.43 | 1.31 | 1.397 | 70,883 |
| 17/04/25 | 1.22 | 1.35 | 1.22 | 1.31 | 102,020 |
|
|
||||
|
|
||||
|
|